Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB-502 and HB-501 alternating 2-vector therapy in HIV
NCT06430905Phase 1Terminated
- Sponsor
- HOOKIPA Pharma
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) (2 arms), sponsored by HOOKIPA Pharma. Primary endpoints: Adverse Events at 48 weeks, Local Injection Site Reactions at 48 weeks and 1 more. Started Jul 2024; status: terminated.
02
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06430905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430905.